Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 3/2014

01-03-2014 | Original paper

A collaborative study of the etiology of breast cancer subtypes in African American women: the AMBER consortium

Authors: Julie R. Palmer, Christine B. Ambrosone, Andrew F. Olshan

Published in: Cancer Causes & Control | Issue 3/2014

Login to get access

Abstract

Purpose

Breast cancer is a heterogeneous disease, with at least five intrinsic subtypes defined by molecular characteristics. Tumors that express the estrogen receptor (ER+) have better outcomes than ER− tumors, due in part to the success of hormonal therapies that target ER+ tumors. The incidence of ER− breast cancer, and the subset of ER− cancers that are basal-like, is about twice as high among African American (AA) women as among US women of European descent (EA). This disparity appears to explain, in part, the disproportionately high mortality from breast cancer that occurs in AA women. Epidemiologic research on breast cancer in AA women lags behind research in EA women. Here, we review differences in the etiology of breast cancer subtypes among AA women and describe a new consortium of ongoing studies of breast cancer in AA women.

Methods

We combined samples and data from four large epidemiologic studies of breast cancer in AA women, two cohort and two case-control, creating the African American Breast Cancer Epidemiology and Risk consortium. Tumor tissue is obtained and stored in tissue microarrays, with assays of molecular markers carried out at a pathology core. Genotyping, carried out centrally, includes a whole exome SNP array and over 180,000 custom SNPs for fine-mapping of genome-wide association studies loci and candidate pathways.

Results

To date, questionnaire data from 5,739 breast cancer cases and 14,273 controls have been harmonized. Genotyping of the first 3,200 cases and 3,700 controls is underway, with a total of 6,000 each expected by the end of the study period.

Conclusions

The new consortium will likely have sufficient statistical power to assess potential risk factors, both genetic and non-genetic, in relation to specific subtypes of breast cancer in AA women.
Literature
1.
Parker JS, Mullins M, Cheang MC et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160–1167PubMedCrossRef
2.
Perou CM, Sorlie T, Eisen MB et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752PubMedCrossRef
3.
Goss PE, Ingle JN, Martino S et al (2007) Efficacy of letrozole extended adjuvant therapy according to estrogen receptor and progesterone receptor status of the primary tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. J Clin Oncol 25(15):2006–2011PubMedCrossRef
4.
Berry DA, Cirrincione C, Henderson IC et al (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295(14):1658–1667PubMedCentralPubMedCrossRef
5.
Burstein HJ, Prestrud AA, Seidenfeld J et al (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28(23):3784–3796PubMedCrossRef
6.
Bardou VJ, Arpino G, Elledge RM et al (2003) Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol 21(10):1973–1979PubMedCrossRef
7.
Jemal A, Ward E, Thun MJ (2007) Recent trends in breast cancer incidence rates by age and tumor characteristics among US women. Breast Cancer Res 9(3):R28PubMedCentralPubMedCrossRef
8.
Anderson WF, Chatterjee N, Ershler WB et al (2002) Estrogen receptor breast cancer phenotypes in the surveillance, epidemiology, and end results database. Breast Cancer Res Treat 76(1):27–36PubMedCrossRef
9.
Chu KC, Anderson WF (2002) Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups. Breast Cancer Res Treat 74(3):199–211PubMedCrossRef
10.
Furberg H, Millikan R, Dressler L et al (2001) Tumor characteristics in African American and white women. Breast Cancer Res Treat 68(1):33–43PubMedCrossRef
11.
Gapstur SM, Dupuis J, Gann P et al (1996) Hormone receptor status of breast tumors in black, Hispanic, and non-Hispanic white women. An analysis of 13,239 cases. Cancer 77(8):1465–1471PubMedCrossRef
12.
Joslyn SA (2002) Racial differences in treatment and survival from early-stage breast carcinoma. Cancer 95(8):1759–1766PubMedCrossRef
13.
Amend K, Hicks D, Ambrosone CB (2006) Breast cancer in African-American women: differences in tumor biology from European-American women. Cancer Res 66(17):8327–8330PubMedCrossRef
14.
Chlebowski RT, Chen Z, Anderson GL et al (2005) Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 97(6):439–448PubMedCrossRef
15.
Yang XR, Sherman ME, Rimm DL et al (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 16(3):439–443PubMedCrossRef
16.
Kim MJ, Ro JY, Ahn SH et al (2006) Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 37(9):1217–1226PubMedCrossRef
17.
Kurebayashi J, Moriya T, Ishida T et al (2007) The prevalence of intrinsic subtypes and prognosis in breast cancer patients of different races. Breast 16(Suppl 2):S72–S77PubMedCrossRef
18.
Lin CH, Liau JY, Lu YS et al (2009) Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia. Cancer Epidemiol Biomarkers Prev 18(6):1807–1814PubMedCrossRef
19.
Bauer KR, Brown M, Cress RD et al (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109(9):1721–1728PubMedCrossRef
20.
Carey LA, Perou CM, Livasy CA et al (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492–2502PubMedCrossRef
21.
Cheang MC, Chia SK, Voduc D et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101(10):736–750PubMedCrossRef
22.
Cheang MC, Voduc D, Bajdik C et al (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14(5):1368–1376PubMedCrossRef
23.
24.
Yang XR, Chang-Claude J, Goode EL et al (2011) Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 103(3):250–263PubMedCrossRef
25.
Palmer JR, Adams-Campbell LL, Boggs DA et al (2007) A prospective study of body size and breast cancer in black women. Cancer Epidemiol Biomarkers Prev 16(9):1795–1802PubMedCrossRef
26.
Trivers KF, Lund MJ, Porter PL et al (2009) The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 20(7):1071–1082PubMedCrossRef
27.
Schatzkin A, Palmer JR, Rosenberg L et al (1987) Risk factors for breast cancer in black women. J Natl Cancer Inst 78(2):213–217PubMed
28.
Ogundiran TO, Huo D, Adenipekun A et al (2010) Case-control study of body size and breast cancer risk in Nigerian women. Am J Epidemiol 172(6):682–690PubMedCrossRef
29.
Palmer JR, Boggs DA, Wise LA et al (2011) Parity and lactation in relation to estrogen receptor negative breast cancer in African American women. Cancer Epidemiol Biomarkers Prev 20(9):1883–1891PubMedCentralPubMedCrossRef
30.
Phipps AI, Chlebowski RT, Prentice R et al (2011) Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst 103(6):470–477PubMedCrossRef
31.
Kwan ML, Kushi LH, Weltzien E et al (2009) Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 11(3):R31PubMedCentralPubMedCrossRef
32.
Shinde SS, Forman MR, Kuerer HM et al (2010) Higher parity and shorter breastfeeding duration: association with triple-negative phenotype of breast cancer. Cancer 116(21):4933–4943PubMedCrossRef
33.
34.
Ma H, Bernstein L, Ross RK et al (2006) Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case-control and a case–case comparison. Breast Cancer Res 8(4):R39PubMedCentralPubMedCrossRef
35.
Rosenberg L, Boggs DA, Wise LA et al (2010) Oral contraceptive use and estrogen/progesterone receptor-negative breast cancer among African American women. Cancer Epidemiol Biomarkers Prev 19(8):2073–2079PubMedCentralPubMedCrossRef
36.
Bernstein L, Teal CR, Joslyn S et al (2003) Ethnicity-related variation in breast cancer risk factors. Cancer 97(1 Suppl):222–229PubMedCrossRef
37.
Kim SY, Dietz PM, England L et al (2007) Trends in pre-pregnancy obesity in nine states, 1993–2003. Obesity (Silver Spring) 15(4):986–993CrossRef
38.
Ogden CL, Carroll MD, Curtin LR et al (2006) Prevalence of overweight and obesity in the United States, 1999–2004. JAMA 295(13):1549–1555PubMedCrossRef
39.
Harvie M, Hooper L, Howell AH (2003) Central obesity and breast cancer risk: a systematic review. Obes Rev 4(3):157–173PubMedCrossRef
40.
Okosun IS, Chandra KM, Boev A et al (2004) Abdominal adiposity in US adults: prevalence and trends, 1960–2000. Prev Med 39(1):197–206PubMedCrossRef
41.
National Institutes of Health/National Heart Lung and Blood (1998) Clinical Guidelines on identification, evaluation, and treatment of overweight and obesity in adults. The evidence report. Obes Res 6:51S–209SCrossRef
42.
National task force on the prevention and treatment of obesity (2000) Overweight, obesity, and health risk. Arch Intern Med 160(7):898–904
43.
Flegal KM, Graubard BI, Williamson DF et al (2005) Excess deaths associated with underweight, overweight, and obesity. JAMA 293(15):1861–1867PubMedCrossRef
44.
Ballard-Barbash R (1994) Anthropometry and breast cancer. Body size—a moving target. Cancer 74(3 Suppl):1090–1100PubMedCrossRef
45.
Despres JP (1993) Abdominal obesity as important component of insulin-resistance syndrome. Nutrition 9(5):452–459PubMed
46.
Kirschner MA, Samojlik E, Drejka M et al (1990) Androgen-estrogen metabolism in women with upper body versus lower body obesity. J Clin Endocrinol Metab 70(2):473–479PubMedCrossRef
47.
Kissebah AH, Krakower GR (1994) Regional adiposity and morbidity. Physiol Rev 74(4):761–811PubMed
48.
Okosun IS, Boltri JM, Anochie LK et al (2004) Racial/ethnic differences in prehypertension in American adults: population and relative attributable risks of abdominal obesity. J Hum Hypertens 18(12):849–855PubMedCrossRef
49.
50.
Hall IJ, Newman B, Millikan RC et al (2000) Body size and breast cancer risk in black women and white women: the Carolina Breast Cancer Study. Am J Epidemiol 151(8):754–764PubMedCrossRef
51.
Lahmann PH, Hoffmann K, Allen N et al (2004) Body size and breast cancer risk: findings from the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 111(5):762–771PubMedCrossRef
52.
van den Brandt PA, Spiegelman D, Yaun SS et al (2000) Pooled analysis of prospective cohort studies on height, weight, and breast cancer risk. Am J Epidemiol 152(6):514–527PubMedCrossRef
53.
Connolly BS, Barnett C, Vogt KN et al (2002) A meta-analysis of published literature on waist-to-hip ratio and risk of breast cancer. Nutr Cancer 44(2):127–138PubMedCrossRef
54.
Althuis MD, Fergenbaum JH, Garcia-Closas M et al (2004) Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 13(10):1558–1568PubMed
55.
Colditz GA, Rosner BA, Chen WY et al (2004) Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 96(3):218–228PubMedCrossRef
56.
Setiawan VW, Monroe KR, Wilkens LR et al (2009) Breast cancer risk factors defined by estrogen and progesterone receptor status: the multiethnic cohort study. Am J Epidemiol 169(10):1251–1259PubMedCrossRef
57.
Adams-Campbell LL, Kim KS, Dunston G et al (1996) The relationship of body mass index to reproductive factors in pre- and postmenopausal African-American women with and without breast cancer. Obes Res 4(5):451–456PubMedCrossRef
58.
Austin H, Cole P, Wynder E (1979) Breast cancer in black American women. Int J Cancer 24(5):541–544PubMedCrossRef
59.
Zhu K, Caulfield J, Hunter S et al (2005) Body mass index and breast cancer risk in African American women. Ann Epidemiol 15(2):123–128PubMedCrossRef
60.
Berstad P, Coates RJ, Bernstein L et al (2010) A case-control study of body mass index and breast cancer risk in white and African-American women. Cancer Epidemiol Biomarkers Prev 19(6):1532–1544PubMedCentralPubMedCrossRef
61.
62.
Hankinson SE, Schernhammer ES (2003) Insulin-like growth factor and breast cancer risk: evidence from observational studies. Breast Dis 17:27–40PubMed
63.
Wiseman M (2008) The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc Nutr Soc 67(3):253–256PubMedCrossRef
64.
Friedenreich CM, Cust AE (2008) Physical activity and breast cancer risk: impact of timing, type and dose of activity and population subgroup effects. Br J Sports Med 42(8):636–647PubMedCrossRef
65.
McTiernan A, Kooperberg C, White E et al (2003) Recreational physical activity and the risk of breast cancer in postmenopausal women: the Women’s Health Initiative Cohort Study. JAMA 290(10):1331–1336PubMedCrossRef
66.
Dallal CM, Sullivan-Halley J, Ross RK et al (2007) Long-term recreational physical activity and risk of invasive and in situ breast cancer: the California teachers study. Arch Intern Med 167(4):408–415PubMedCrossRef
67.
Bernstein L, Patel AV, Ursin G et al (2005) Lifetime recreational exercise activity and breast cancer risk among black women and white women. J Natl Cancer Inst 97(22):1671–1679PubMedCrossRef
68.
Peters TM, Schatzkin A, Gierach GL et al (2009) Physical activity and postmenopausal breast cancer risk in the NIH-AARP diet and health study. Cancer Epidemiol Biomarkers Prev 18(1):289–296PubMedCentralPubMedCrossRef
69.
Adams SA, Matthews CE, Hebert JR et al (2006) Association of physical activity with hormone receptor status: the Shanghai Breast Cancer Study. Cancer Epidemiol Biomarkers Prev 15(6):1170–1178PubMedCentralPubMedCrossRef
70.
Bardia A, Hartmann LC, Vachon CM et al (2006) Recreational physical activity and risk of postmenopausal breast cancer based on hormone receptor status. Arch Intern Med 166(22):2478–2483PubMedCrossRef
71.
Enger SM, Ross RK, Paganini-Hill A et al (2000) Body size, physical activity, and breast cancer hormone receptor status: results from two case-control studies. Cancer Epidemiol Biomarkers Prev 9(7):681–687PubMed
72.
Palmer JR, Ruiz-Narvaez EA, Rotimi CN et al (2013) Genetic susceptibility loci for subtypes of breast cancer in an African American population. Cancer Epidemiol Biomarkers Prev 22(1):127–134PubMedCentralPubMedCrossRef
73.
Fejerman L, Haiman CA, Reich D et al (2009) An admixture scan in 1,484 African American women with breast cancer. Cancer Epidemiol Biomarkers Prev 18(11):3110–3117PubMedCentralPubMedCrossRef
74.
Nesby-O’Dell S, Scanlon KS, Cogswell ME et al (2002) Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988–1994. Am J Clin Nutr 76(1):187–192PubMed
75.
Ginde AA, Liu MC, Camargo CA Jr (2009) Demographic differences and trends of vitamin D insufficiency in the US population, 1988–2004. Arch Intern Med 169(6):626–632PubMedCentralPubMedCrossRef
76.
Yao S, Zirpoli G, Bovbjerg DH et al (2012) Variants in the vitamin D pathway, serum levels of vitamin D, and estrogen receptor negative breast cancer among African-American women: a case-control study. Breast Cancer Res 14(2):R58PubMedCentralPubMedCrossRef
77.
Bauer SR, Hankinson SE, Bertone-Johnson ER et al (2013) Plasma vitamin D levels, menopause, and risk of breast cancer: dose-response meta-analysis of prospective studies. Medicine (Baltimore) 92(3):123–131CrossRef
78.
Yao S, Sucheston LE, Millen AE et al (2011) Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: a case-control and a case-series study. PLoS ONE 6(2):e17251PubMedCentralPubMedCrossRef
79.
Peppone LJ, Rickles AS, Janelsins MC et al (2012) The association between breast cancer prognostic indicators and serum 25-OH vitamin D levels. Ann Surg Oncol 19(8):2590–2599PubMedCrossRef
80.
81.
Kawase T, Matsuo K, Suzuki T et al (2010) Association between vitamin D and calcium intake and breast cancer risk according to menopausal status and receptor status in Japan. Cancer Sci 101(5):1234–1240PubMedCrossRef
82.
Eliassen AH, Spiegelman D, Hollis BW et al (2011) Plasma 25-hydroxyvitamin D and risk of breast cancer in the Nurses’ Health Study II. Breast Cancer Res 13(3):R50PubMedCentralPubMedCrossRef
83.
Blackmore KM, Lesosky M, Barnett H et al (2008) Vitamin D from dietary intake and sunlight exposure and the risk of hormone-receptor-defined breast cancer. Am J Epidemiol 168(8):915–924PubMedCrossRef
84.
Heikkila K, Ebrahim S, Lawlor DA (2007) A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health 61(9):824–833PubMedCrossRef
85.
Gong Z, Quan L, Yao S et al (2013) Innate immunity pathways and breast cancer risk in African American and European-American women in the Women’s Circle of Health Study (WCHS). PLoS One 8(8):e72619
86.
Quan L, Gong Z, Yao S et al (2013) Cytokine and cytokine receptor genes of adaptive immune response are differentially associated with breast cancer risk in American women of African and European ancestry. Int J Cancer. doi:10.​1002/​ijc.​28458
87.
Pierce BL, Ballard-Barbash R, Bernstein L et al (2009) Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol 27(21):3437–3444PubMedCrossRef
88.
Lyon DE, McCain NL, Walter J et al (2008) Cytokine comparisons between women with breast cancer and women with a negative breast biopsy. Nurs Res 57(1):51–58PubMedCentralPubMedCrossRef
89.
Rao VS, Dyer CE, Jameel JK et al (2006) Potential prognostic and therapeutic roles for cytokines in breast cancer (Review). Oncol Rep 15(1):179–185PubMed
90.
Ness RB, Haggerty CL, Harger G et al (2004) Differential distribution of allelic variants in cytokine genes among African Americans and White Americans. Am J Epidemiol 160(11):1033–1038PubMedCrossRef
91.
Zabaleta J, Schneider BG, Ryckman K et al (2008) Ethnic differences in cytokine gene polymorphisms: potential implications for cancer development. Cancer Immunol Immunother 57(1):107–114PubMedCrossRef
92.
93.
Campbell MC, Tishkoff SA (2008) African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Annu Rev Genomics Hum Genet 9:403–433PubMedCentralPubMedCrossRef
94.
Shen H, Schuster R, Stringer KF et al (2006) The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth. FASEB J 20(1):59–64PubMedCrossRef
95.
Hong CC, Yao S, McCann SE et al (2013) Pretreatment levels of circulating Th1 and Th2 cytokines, and their ratios, are associated with ER-negative and triple negative breast cancers. Breast Cancer Res Treat 139(2):477–488PubMedCentralPubMedCrossRef
96.
Chen F, Chen GK, Millikan RC et al (2011) Fine-mapping of breast cancer susceptibility loci characterizes genetic risk in African Americans. Hum Mol Genet 20(22):4491–4503PubMedCrossRef
97.
98.
Huo D, Zheng Y, Ogundiran TO et al (2012) Evaluation of 19 susceptibility loci of breast cancer in women of African ancestry. Carcinogenesis 33(4):835–840PubMedCrossRef
99.
Michailidou K, Hall P, Gonzalez-Neira A et al (2013) Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet 45(4):353–361, 361e1-2PubMedCrossRef
100.
Garcia-Closas M, Couch FJ, Lindstrom S et al (2013) Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet 45(4):392–398, 398e1-2PubMedCrossRef
101.
Zheng W, Cai Q, Signorello LB et al (2009) Evaluation of 11 breast cancer susceptibility loci in African-American women. Cancer Epidemiol Biomarkers Prev 18(10):2761–2764PubMedCentralPubMedCrossRef
102.
Ruiz-Narvaez EA, Rosenberg L, Rotimi CN et al (2010) Genetic variants on chromosome 5p12 are associated with risk of breast cancer in African American women: the Black Women’s Health Study. Breast Cancer Res Treat 123(2):525–530PubMedCentralPubMedCrossRef
103.
Hutter CM, Young AM, Ochs-Balcom HM et al (2011) Replication of breast cancer GWAS susceptibility loci in the Women’s Health Initiative African American SHARe Study. Cancer Epidemiol Biomarkers Prev 20(9):1950–1959PubMedCentralPubMedCrossRef
104.
Haiman CA, Chen GK, Vachon CM et al (2011) A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet 43(12):1210–1214PubMedCentralPubMedCrossRef
105.
Newman B, Moorman PG, Millikan R et al (1995) The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology. Breast Cancer Res Treat 35(1):51–60PubMedCrossRef
106.
McGee SA, Durham DD, Tse CK et al (2013) Determinants of breast cancer treatment delay differ for African American and white women. Cancer Epidemiol Biomarkers Prev 22(7):1227–1238PubMedCrossRef
107.
Ambrosone CB, Ciupak GL, Bandera EV et al (2009) Conducting molecular epidemiological research in the age of HIPAA: a multi-institutional case-control study of breast cancer in African-American and European-American Women. J Oncol 2009:871250PubMedCentralPubMedCrossRef
108.
Bandera EV, Chandran U, Zirpoli G et al (2013) Rethinking sources of representative controls for the conduct of case-control studies in minority populations. BMC Med Res Methodol 13:71PubMedCentralPubMedCrossRef
109.
Rosenberg L, Rao RS, Palmer JR (2003) A case-control study of acetaminophen use in relation to the risk of first myocardial infarction in men. Pharmacoepidemiol Drug Saf 12(6):459–465PubMedCrossRef
110.
Cozier YC, Palmer JR, Rosenberg L (2004) Comparison of methods for collection of DNA samples by mail in the Black Women’s Health Study. Ann Epidemiol 14(2):117–122PubMedCrossRef
111.
Kolonel LN, Henderson BE, Hankin JH et al (2000) A multiethnic cohort in Hawaii and Los Angeles: baseline characteristics. Am J Epidemiol 151(4):346–357PubMedCrossRef
112.
Khoury MJ, Wacholder S (2009) Invited commentary: from genome-wide association studies to gene-environment-wide interaction studies—challenges and opportunities. Am J Epidemiol 169(2):227–230; discussion 234–235PubMedCrossRef
Metadata
Title
A collaborative study of the etiology of breast cancer subtypes in African American women: the AMBER consortium
Authors
Julie R. Palmer
Christine B. Ambrosone
Andrew F. Olshan
Publication date
01-03-2014
Publisher
Springer International Publishing
Published in
Cancer Causes & Control / Issue 3/2014
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-013-0332-8

Other articles of this Issue 3/2014

Cancer Causes & Control 3/2014 Go to the issue

Original Paper

The influence of genetic ancestry and ethnicity on breast cancer survival associated with genetic variation in the TGF-β-signaling pathway: The Breast Cancer Health Disparities Study

Original paper

Urinary lignans and inflammatory markers in the US National Health and Nutrition Examination Survey (NHANES) 1999–2004 and 2005–2008

Original paper

Fasting insulin and endogenous hormones in relation to premenopausal breast density (Canada)

Original paper

Association between endogenous sex steroid hormones and insulin-like growth factor proteins in US men

Letter to the Editor

Is the trend in primary penile cancer in England real?

Original Paper

The joint contribution of tumor phenotype and education to breast cancer survival disparity between Hispanic and non-Hispanic white women
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits